GlassScriptPhysician profile
Lisa Hohl
NPI 1235373705
$4,005.87
in general payments reported to CMS, 2019-2025
29 companies · $966 in 2025
The $966 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $563 · 2023: $901 · 2024: $957 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $547.13 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $522.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $420.46 | 2021-2025 | |
| Pfizer INC. | $419.17 | 2021-2025 | |
| Lilly USA, LLC | $266.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $248.04 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $203.51 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $171.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $144.90 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $130.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Abbott Laboratories | $124.02 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.30 | 2021-2023 | Jardiance, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $86.69 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $67.52 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.49 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $46.62 | 2022-2025 | |
| Daiichi Sankyo INC. | $39.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.51 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $36.38 | 2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $32.50 | 2021-2023 | Camzyos |
| Esperion Therapeutics, INC. | $23.03 | 2023 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.07 | 2022 | |
| Biomarin Pharmaceutical INC. | $19.48 | 2024 | Voxzogo 1.2mg |
| Biogen, INC. | $19.15 | 2024 | Spinraza |
| Lundbeck LLC | $18.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.